# A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes

> **NCT03987919** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 1879 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT03987919
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-30
- **Primary completion:** 2021-01-28
- **Final completion:** 2021-02-15
- **Target enrollment:** 1879 (ACTUAL)
- **Last updated:** 2022-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03987919

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03987919, "A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03987919. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*